Provided by Tiger Trade Technology Pte. Ltd.

Tyra Biosciences, Inc.

20.43
-0.5800-2.76%
Post-market: 20.430.00000.00%19:30 EDT
Volume:1.05M
Turnover:21.43M
Market Cap:1.40B
PE:-8.50
High:21.39
Open:21.25
Low:20.17
Close:21.01
52wk High:40.65
52wk Low:12.98
Shares:68.76M
Float Shares:40.01M
Volume Ratio:1.12
T/O Rate:2.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4031
EPS(LYR):-2.0125
ROE:-45.31%
ROA:-28.46%
PB:3.97
PE(LYR):-10.15

Loading ...

Tyra Biosciences Reports 79% Response Rate in Phase 2 Bladder Cancer Study of Dabogratinib at 60 Mg Dose

Reuters
·
Sep 09

Tyra Biosciences, - Announces Initial Phase 2 Surf302 Results for Oral Dabogratinib

THOMSON REUTERS
·
Sep 09

Tyra Biosciences to Present at Cantor Global Healthcare Conference 2026

Reuters
·
Sep 09

Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Tyra Bioscience (TYRA)

TIPRANKS
·
Sep 08

U.S. Small Caps Close Up; Tyra Biosciences Climbs Highest

Dow Jones
·
Sep 05

Tyra Biosciences Price Target Maintained with a $45.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 05

Tyra Biosciences: Buy Rating Reiterated as SURF302 Data Upside Beckons; 12‑Month Price Target Maintained at $45

TIPRANKS
·
Sep 04

Tyra Biosciences to Present Initial Phase 2 Surf302 Data for Oral Dabogratinib in Intermediate-Risk Bladder Cancer on Sept. 9

Reuters
·
Sep 04

Tyra Bioscience (TYRA) Gets a Buy from Bank of America Securities

TIPRANKS
·
Aug 11

BofA Adjusts Price Target on Tyra Bioscience to $39 From $42

MT Newswires Live
·
Aug 11

Climb Bio Q2 Net Loss Widens on Pipeline Advancement

Reuters
·
Aug 06

Enliven Therapeutics Q2 Net Loss Widens on Higher Expenses

Reuters
·
Aug 06

Tyra Biosciences price target lowered to $42 from $44 at Jefferies

TIPRANKS
·
Aug 06

Tyra Biosciences delayed cancer data by one month, says JonesResearch

TIPRANKS
·
Aug 06

Tyra Biosciences falls 20% after pushing data readout to September from August

TIPRANKS
·
Aug 06

Kymera Therapeutics Q2 Collaboration Revenue More than Doubles, Beats Estimates

Reuters
·
Aug 05

Analysts Are Bullish on Top Healthcare Stocks: Alphatec Holdings (ATEC), Tyra Bioscience (TYRA)

TIPRANKS
·
Aug 05

Tyra Biosciences Q2 EPS $(0.69) Misses $(0.65) Estimate

Benzinga Earnings
·
Aug 05

Tyra Biosciences - Amends Sales Agreement on Aug 4, 2026 to Increase Maximum Offering Price for Common Stock - SEC Filing

THOMSON REUTERS
·
Aug 05

Tyra Biosciences - May Offer and Sell up to $250 Mln of Common Stock Under Amended Sales Agreement - SEC Filing

THOMSON REUTERS
·
Aug 05